Cingulate INC Form 4 insider transactions

Cingulate Inc.'s CEO, Shane J. Schaffer, acquired stock options for 57,323 shares on March 4, 2024, according to a Form 4 filing with the SEC.

Director John A. Roberts of Cingulate Inc. reports the acquisition of stock options.

Director Peter J. Werth acquired stock options in Cingulate Inc. in lieu of cash retainer fees.

Director Jeffrey S. Ervin acquired 5,000 stock options in Cingulate Inc. on March 4, 2024, at an exercise price of $1.18.

Raul R. Silva, EVP and CSO of Cingulate Inc., reports the acquisition of stock options in the company.

Director Bryan Jay Lawrence reports acquisition of 5,000 stock options in Cingulate Inc.

EVP and Chief Medical Officer of Cingulate Inc., Matthew Brams, reports the acquisition of stock options.

Jennifer L. Callahan, SVP and CFO of Cingulate Inc., reports the acquisition of stock options.

Laurie Myers, EVP and COO of Cingulate Inc., reports the acquisition of stock options.